emtricitabine+tenofovir disoproxil sandoz 200 mg + 245 mg tabletki powlekane
sandoz gmbh - emtricitabinum + tenofovirum disoproxilum - tabletki powlekane - 200 mg + 245 mg
emtricitabine/tenofovir stada 200 mg + 245 mg tabletki powlekane
stada arzneimittel ag - emtricitabinum + tenofovirum disoproxilum - tabletki powlekane - 200 mg + 245 mg
valcyclox 450 mg tabletki powlekane
stada arzneimittel ag - valganciclovirum - tabletki powlekane - 450 mg
tenofovir disoproxil accord 245 mg tabletki powlekane
accord healthcare polska sp. z o.o. - tenofovirum disoproxilum - tabletki powlekane - 245 mg
tenofovir disoproxil aurovitas 245 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - tenofovirum disoproxilum - tabletki powlekane - 245 mg
atazanavir zentiva 150 mg kapsułki twarde
zentiva, k.s. - atazanaviri sulfas - kapsułki twarde - 150 mg
atazanavir zentiva 200 mg kapsułki twarde
zentiva, k.s. - atazanaviri sulfas - kapsułki twarde - 200 mg
atazanavir zentiva 300 mg kapsułki twarde
zentiva, k.s. - atazanaviri sulfas - kapsułki twarde - 300 mg
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - Środki przeciwnowotworowe - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
tenofovir disoproxil accordpharma 245 mg tabletki powlekane
accord healthcare polska sp. z o.o. - tenofovirum disoproxilum - tabletki powlekane - 245 mg